Institutional Investor Sentiment About Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) Increased

May 21, 2018 - By Maria Brooks

Sentiment for Ultragenyx Pharmaceutical Inc (NASDAQ:RARE)

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) institutional sentiment increased to 1.25 in 2017 Q4. Its up 0.06, from 1.19 in 2017Q3. The ratio increased, as 70 investment managers started new or increased holdings, while 56 cut down and sold equity positions in Ultragenyx Pharmaceutical Inc. The investment managers in our partner’s database now have: 42.32 million shares, up from 39.75 million shares in 2017Q3. Also, the number of investment managers holding Ultragenyx Pharmaceutical Inc in their top 10 holdings decreased from 1 to 0 for a decrease of 1. Sold All: 14 Reduced: 42 Increased: 51 New Position: 19.

Ultragenyx Pharmaceutical Inc., a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. The company has market cap of $3.29 billion. The firm is developing various biologics product candidates, including KRN23, a human monoclonal antibody that in Phase III adult study to bind and reduce the biological activity of fibroblast growth factor 23 to enhance abnormally low phosphate levels in patients with X-linked hypophosphatemia, as well as for the treatment of tumor-induced osteomalacia. It currently has negative earnings. The Company’s biologics product candidates also comprise recombinant human beta -glucuronidase , an enzyme replacement therapy, which completed the Phase 3 clinical study for the treatment of mucopolysaccharidosis 7; and recombinant human protective protein cathepsin-A (rhPPCA), an enzyme replacement therapy, which is in preclinical development for galactosialidosis.

The stock increased 0.33% or $0.22 during the last trading session, reaching $66.15. About 36,653 shares traded. Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) has declined 29.39% since May 21, 2017 and is downtrending. It has underperformed by 40.94% the S&P500.

Analysts await Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to report earnings on July, 26. They expect $-2.10 earnings per share, down 22.09 % or $0.38 from last year’s $-1.72 per share. After $0.62 actual earnings per share reported by Ultragenyx Pharmaceutical Inc. for the previous quarter, Wall Street now forecasts -438.71 % negative EPS growth.

Iguana Healthcare Management Llc holds 1.51% of its portfolio in Ultragenyx Pharmaceutical Inc. for 50,000 shares. Opaleye Management Inc. owns 90,000 shares or 1.34% of their US portfolio. Moreover, Abingworth Llp has 1.28% invested in the company for 38,100 shares. The Illinois-based Columbia Wanger Asset Management Llc has invested 1% in the stock. Pier Capital Llc, a Connecticut-based fund reported 125,728 shares.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Ratings Coverage

Ratings analysis reveals 93% of Ultragenyx Pharmaceutical’s analysts are positive. Out of 14 Wall Street analysts rating Ultragenyx Pharmaceutical, 13 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. The lowest target is $61 while the high is $80.0. The stock’s average target of $67.27 is 1.69% above today’s ($66.15) share price. RARE was included in 17 notes of analysts from December 4, 2017. Canaccord Genuity maintained Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) on Wednesday, April 18 with “Buy” rating. The rating was upgraded by Barclays Capital to “Overweight” on Friday, May 11. Wedbush maintained the stock with “Buy” rating in Wednesday, April 18 report. Bank of America maintained Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) on Wednesday, February 21 with “Buy” rating. Evercore upgraded the shares of RARE in report on Monday, January 22 to “Outperform” rating. Canaccord Genuity maintained it with “Buy” rating and $80.0 target in Tuesday, December 5 report. On Wednesday, April 18 the stock rating was maintained by Stifel Nicolaus with “Buy”. The rating was maintained by Wedbush on Friday, January 5 with “Buy”. The firm earned “Buy” rating on Wednesday, February 21 by Stifel Nicolaus. SunTrust upgraded the shares of RARE in report on Wednesday, April 18 to “Buy” rating.

More notable recent Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) news were published by: Globenewswire.com which released: “Ultragenyx Announces Filing and FDA Clearance of an Investigational New Drug Application for DTX401, a Gene …” on April 23, 2018, also Streetinsider.com with their article: “Omega’s 13F Shows Increase in Ocwen (OCN), Synchrony (SYF), United (UAL), Exits Zynga (ZNGA) (More…)” published on May 15, 2018, Fool.com published: “Sangamo Therapeutics Stock History” on May 17, 2018. More interesting news about Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) were released by: Seekingalpha.com and their article: “Premarket analyst action – healthcare” published on May 11, 2018 as well as Globenewswire.com‘s news article titled: “Ultragenyx Reports First Quarter 2018 Financial Results and Corporate Update” with publication date: May 07, 2018.

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter: